Ardelyx, Inc.
Company & revenue
About Ardelyx, Inc.
Financial breakdown: year ended 2025-12-31
Who they are
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor.
Brands & revenue mix
A minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation.
Reported revenue share.Source
A phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
Reported revenue share.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Customer concentrationPREMIUM
The company does not disclose specific major customer concentration in its recent filings, as its business model focuses on the commercialization of biopharmaceutical products through broader market channels.
Business relationships & partnershipsPREMIUM
- Kyowa Kirin Co., Ltd. — Exclusive license agreement entered into in November 2017, with a second amendment in April 2022, regarding the development and commercialization of products.Source
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
22
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
27
Poor
Financial Strength
16
Business Quality / Moat
49
Management
0
Growth Quality
57
Risk / Durability
18
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
25
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
38/100
Building Historical Record
Model Score 38/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for ARDX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ARDX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can ARDX fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Is ARDX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What specifically needs to improve for ARDX to reach sustainable profitability?
- •What future growth or profitability would be needed to justify ARDX's current valuation?
Essential Investment Snapshot
Wall Street Score
22
Opportunity Score
25
Market Cap
$825.1M
P/E Ratio
-15.2
EPS
$-0.23
52-Week High
$8.40
52-Week Low
$3.31
Beta
0.69
Analyst Target
$13.00
Shares Outstanding
241.0M
Total Revenue
$450.9M
Total Debt
$256.2M
Dividend
No current dividend
Liquidation Value / Share
$0.62
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ARDX
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-1.4x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on ARDX.
What the Bulls Say
- +Material partnership/catalyst: Exclusive license agreement entered into in November 2017, with a second amendment in April 2022, regarding the development and commercialization of products.
- +Product opportunity: Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also cu.
What the Bears Say
- −Negative free cash flow may increase the need for outside financing and dilution.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
22
Sep 8, 2026
Change
+0.2
points
Current Score
22
Oct 1, 2026
Category Changes
ARDX increased 0.2 points because overall fundamentals improved.
Projected Score
Projected Score
21
Projected Change
-100.0%
Preliminary comparable-period financial changes suggest decline of approximately 1.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$3.34
Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Related Companies
BiotechnologyNews
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ARDX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial